Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Inflation Prevention Act This bill establishes a point of order that, when the annualized rate of inflation exceeds 4.5%, prohibits the Senate from considering legislation that provides new budget authority and is estimated to result in an increase to the rate of inflation. The prohibition may be waived by an affirmative vote of three-fifths of the Senate.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2022 · fourth_quarter · Pharmacy
Prescription Drug Costs. Drug Pricing. H.R.2868: Protecting Access to Affordable Medicines Act of 2021. S.2910: Expanding Access to Low-Cost Generics Act of 2021. H.R.5237: Reduced Costs and Continued Cures Act of 2021. H.R.6000: Cures 2.0 Act. H.R.7032/S.4338: Increasing Transparency in Generic Drug Applications Act. H.R.7472/S.4026: Discounted Drugs for Clinical Trials Act. H.R.5030/S.2706: DIVERSE Trials Act. H.R.3085/S.1548: ENACT Act of 2021. H.R.6584: DEPICT Act. Pre-Hatch-Waxman ANDAs (PANDAs). H.R.6963: Accelerated Approval Integrity Act of 2022. H.R.6996: Accelerating Access for Patients Act of 2022. S.3576: ADAPT 2.0 Act. H.R.7008: Pre-approval Information Exchange Act of 2022. H.R.2831: Prompt Approval of Safe Generic Drugs Act. H.R.6431: Data Transparency and Drug Safety Act of 2022. Civil Monetary Penalties. Pharmaceutical Exclusivity. 180-Day Exclusivity. H.R.2853: BLOCKING Act of 2021. S.4918: Increasing Prescription Drug Competition Act. Labeling of Generic Drugs and Biosimilars. H.R.9011: Updated Drug Labeling for Patient Safety Act. H.R.6973/S.4351: Enhanced Access to Affordable Medicines Act of 2022. Section 505(j)(10) Labeling [Legislation not yet introduced]. S.2628: Better ODDS To Reduce Diversion Act of 2021. S.1462: Simplifying the Generic Drug Application Process Act. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. Generic Formulations. H.R.7473: Generic Substitution Noninterference Act. Incentivize Domestic Manufacturing. H.R.6381/S.3521: CREATE Act of 2022. Drug Shortages. Stockpile of Generic Drugs. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. Biosimilar User Fee Act (BsUFA). BsUFA III Negotiations. Biosimilars Insulin. Cost Sharing for Biosimilars. S.6: Biosimilar Red Tape Elimination Act. H.R.7047: Lowering Costs by Improving Biosimilar Uptake Act. Hybrid Biosimilar Applications [Legislation not yet introduced]. 505(b)(2) Biosimilar Proposal. Same Strength Requirement for Biosimilars. H.R.2565/S.2952: FDA Modernization Act of 2021. H.R.7377/S.1463: Modernizing Therapeutic Equivalence Rating Determination Act. FDA Inspections. Energy & Commerce Factory Inspection Legislation. H.R.7006: INSPECTIONS Act. H.R.6980: HHS Inspections Pilot Program. S.3509: Creating Efficiency in Foreign Facility Inspections Act. FDA-PTO Collaboration. FDA Genus Decision. FDA Catalyst Decision. 506I Marketing Status Updates. H.R.6483: Improved Transparency of Foreign Drug Manufacturing Act of 2022. H.R.7667: Food and Drug Amendments of 2022. H.R.6988: Drug Manufacturing Innovation Act of 2022. S.4348: FDASLA Act of 2022. H.R.7035/S.4302: Biologics Market Transparency Act of 2022. Buy American Proposals. Issues Related to COVID-19. Implementation of the Inflation Reduction Act.. H.R.6485/S.3495: Inflation Prevention Act. S.3799: PREVENT Pandemics Act. H.R.2617: Consolidated Appropriations Act of 2023.
Read twice and referred to the Committee on Rules and Administration.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $900,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE
2022 · fourth_quarter · Medicare/Medicaid
Medicare Part D Reform. Medicare Part D Program and Generic Drugs. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program. Medicare Part D Tiering. H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. Rebates and Pharmacy Benefit Managers (PBMs). H.R.2868: Protecting Access to Affordable Medicines Act of 2021. Medicare Price Negotiation. H.R.5260: Reduced Costs and Continued Cures Act. Medicare Shared Savings Program. H.R.2869/S.1427: Increasing Access to Biosimilars Act of 2021. ASP+8%. H.R.2815: BIOSIM Act. Implementation of the Inflation Reduction Act. H.R.6485/S.3495: Inflation Prevention Act.
Client expense: $900,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Pharmacy
Prescription Drug Costs. Drug Pricing. H.R.2868: Protecting Access to Affordable Medicines Act of 2021. S.2910: Expanding Access to Low-Cost Generics Act of 2021. H.R.5237: Reduced Costs and Continued Cures Act of 2021. H.R.6000: Cures 2.0 Act. H.R.7032/S.4338: Increasing Transparency in Generic Drug Applications Act of 2022. H.R.7472/S.4026: Discounted Drugs for Clinical Trials Act. H.R.5030/S.2706: DIVERSE Trials Act. H.R.3085/S.1548: ENACT Act of 2021. H.R.6584: DEPICT Act. Pre-Hatch-Waxman ANDAs (PANDAs). H.R.6963: Accelerated Approval Integrity Act of 2022. H.R.6996: Accelerating Access for Patients Act of 2022. S.3576: ADPT 2.0 Act. H.R.7008: Pre-approval Information Exchange Act of 2022. H.R.2831: Prompt Approval of Safe Generic Drugs Act. H.R.6431: Data Transparency and Drug Safety Act of 2022. Civil Monetary Penalties. Pharmaceutical Exclusivity. 180-Day Exclusivity. H.R.2853: BLOCKING Act of 2021. Labeling of Generic Drugs and Biosimilars. H.R.6973/S.4351: Enhanced Access to Affordable Medicines Act of 2022. Section 505(j)(10) Labeling [Legislation not yet introduced]. S.2628: Better ODDS To Reduce Diversion Act of 2021. S.1462: Simplifying the Generic Drug Application Process Act. Generic carveouts patent protected information in drug labels, including issues related to GSK v. Teva. Generic Formulations. H.R.7473: Generic Substitution Noninterference Act. Incentivize domestic manufacturing. H.R.6381/S.3521: CREATE Act of 2022. Drug Shortages. Stockpile of Generic Drugs. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. Biosimilar User Fee Act (BsUFA). BsUFA III Negotiations. Biosimilars Insulin. Cost Sharing for Biosimilars. H.R.7047: Lowering Costs by Improving Biosimilar Uptake Act. Hybrid Biosimilar Applications [Legislation not yet introduced]. 505(b)(2) Biosimilar Proposal. Same Strength Requirement for Biosimilars. H.R.2565/S.2952: FDA Modernization Act of 2021. H.R.7377/S.1463: Modernizing Therapeutic Equivalence Rating Determination Act. FDA Inspections. Inspections Legislative Proposals. Energy and Commerce Factory Inspection Legislation. H.R.7006: INSPECTIONS Act. H.R.6980: HHS Inspections Pilot Program. S.3509: Creating Efficiency in Foreign Facility Inspections Act. FDA-PTO Collaboration. FDA Genus Decision. FDA Catalyst Decision. 506I Marketing Status Updates. H.R.6483: Improved Transparency of Foreign Drug Manufacturing Act of 2022. H.R.7667: Food and Drug Amendments of 2022. H.R.6988: Drug Manufacturing Innovation Act of 2022. S.4348: FDASLA Act of 2022. H.R.7035/S.4302: Biologics Market Transparency Act of 2022. Buy American Proposals. Issues Related to COVID-19. H.R.748/S.3548: CARES Act Reporting. H.R.5376: Inflation Reduction Act of 2022. H.R.6485/S.3495: Inflation Prevention Act. S.3799: PREVENT Pandemics Act.
Client expense: $720,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2022 · third_quarter · Medicare/Medicaid
Medicare Part D Reform. Medicare Part D Program and Generic Drugs. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program. Medicare Part D Tiering. H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. Rebates and Pharmacy Benefit Managers (PBMs). H.R.2868: Protecting Access to Affordable Medicines Act of 2021. Medicare Price Negotiation. H.R.5260: Reduced Costs and Continued Cures Act. Medicare Shared Savings Program. H.R.2869/S.1427: Increasing Access to Biosimilars Act of 2021. ASP+8%. H.R.2815:BIOSIM Act. H.R.5376: Inflation Reduction Act of 2022. H.R.6485/S.3495: Inflation Prevention Act.
Client expense: $720,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Medicare/Medicaid
H.R.1791 - CHIPP Act/Childrens Health Insurance Program Permanency Act S.646, H.R.1738 - Stabilize Medicaid and CHIP Coverage Act of 2021 H.R.3345 - Helping MOMS Act of 2021 H.R.265 - Insular Area Medicaid Parity Act H.R.955, S.285 - Medicaid Reentry Act of 2021 H.R. 4406 - the Supporting Medicaid in the U.S. Territories Act redeterminations / end of the Public Health Emergency continuous eligibility and eFMAP/MOE Federal Medicaid payment deferral telehealth behavioral health social determinants of health prescription drug coverage text/mobile beneficiary outreach/TCPA dually eligible Medicare/Medicaid population COVID-19 pandemic S. 3495, H.R.5376 - Inflation Reduction Act of 2022
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Trade (domestic/foreign)
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Medical/Disease Research/Clinical Labs
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Taxation/Internal Revenue Code
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Copyright/Patent/Trademark
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Pharmacy
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Medicare/Medicaid
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Science/Technology
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · third_quarter · Health Issues
User fee reauthorization (HR 7667) (S.4535) (S.4348) - Prescription drug, Biosimilars, and medical device user fee program reauthorization, accelerated approval, importation, lab test issues Inflation Reduction Act (S.3495) - drug pricing, Medicare and Medicaid coverage of prescription drugs Intellectual property - patents, "march-in" rights Tax and trade issues - SBIR, SBA, compulsory licensing, international pricing issues
Client expense: Not reported · Firm income: Not reported
2022 · first_quarter · Budget/Appropriations
H.R. 6628/S. 3889Congressional Power of the Purse Act H.R. 1319/S. Amdt 891American Rescue Plan Act of 2021 H.R. 412Congressional Death Gratuity payments H.R. 1086Earmark Elimination Act H.R. 3785Fair-Value Accounting and Budget Act H.R. 3684Infrastructure Investment and Jobs Act Internal Revenue Service budget request H.R. 4521America COMPETES Act S. 1260U.S. Innovation and Competition Act (USICA) H.R. 3967Honoring our PACT Act State and Local Fiscal Recovery Funds (SLFRF) program under the American Rescue Plan Act (ARPA) Supplemental funding requests for COVID-19 public health spending Supplemental funding requests for Ukraine H.R. 2471Consolidated Appropriations Act, 2022 President Biden's FY 2023 budget request H.R. 3807Relief for Restaurants and other Hard Hit Small Businesses Act S. 3495 / H.R. 6485Inflation Prevention Act Congressional budget process reform S. 2744Restraining Emergency War Spending Act S. 272 / H.R. 22Congressional Budget Justification Transparency Act S. 3289 / H.R. 6115DISASTER Act H.R. 7147Cost of War Act of 2022 H.R. 5376Build Back Better Act Stimulus for businesses impacted by the COVID-19 pandemic
Client expense: $30,000 · Firm income: Not reported
| Republican |
| OK |
| John Hoeven | Republican | ND |
| John Thune | Republican | SD |
| Joni Ernst | Republican | IA |
| Kevin Cramer | Republican | ND |
| Marco Rubio | Republican | FL |
| Patrick J. Toomey | Republican | PA |
| Rick Scott | Republican | FL |
| Steve Daines | Republican | MT |
| Todd Young | Republican | IN |
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office